Image
ABOUT
Sean P. Nolan
Independent Director
Director since 2019
Compensation and Nominating, Governance and Corporate Responsibility Committees
Director since 2019
Compensation and Nominating, Governance and Corporate Responsibility Committees
Key Experience and Qualifications
Mr. Nolan brings to our Board nearly 30 years of experience in the life sciences industry as a public company executive, operator and serial entrepreneur. His diverse functional expertise includes commercial operations, global marketing, and corporate and business development. Mr. Nolan previously served as CEO of AveXis (NYSE: AVXS), which he grew from four employees to a fully integrated global public company with research, clinical, regulatory, manufacturing and commercial operations that was ultimately sold to Novartis for $8.7 billion.
Professional Experience
- Taysha Gene Therapies, Inc. (NASDAQ: TSHA)
- Chief Executive Officer (since 2022)
- Chair of the Board (since 2020)
- President, Nolan Capital, LLC, an investment fund (since 2019)
- President and Chief Executive Officer, AveXis, Inc. (formerly NASDAQ: AVXS), a gene therapy company (2015-2018)
- Chief Business Officer, InterMune, Inc. (formerly NASDAQ: ITMN), a biopharmaceutical company (2013-2015)
- Chief Commercial Officer, Reata Pharmaceuticals, Inc. (NASDAQ: RETA), a pharmaceuticals company (2011-2012)
- Chief Commercial Officer and President, Lundbeck, Inc., a U.S. affiliate of H. Lundbeck A/S, a Danish pharmaceuticals company (2009-2010)
- Director, Neoleukin Therapeutics (now Neurogene, Inc.) (NASDAQ: NLTX) (2019-2020)
- Director, Aquinox Pharmaceuticals, Inc. (formerly NASDAQ: AQXP) (2015-2019)
Private Boards and Community Service
- Chairman of the Board, Jaguar Gene Therapy, LLC
- Chairman of the Board, Affinia Therapeutics Inc.
- Chairman of the Board, Encoded Therapeutics, Inc.
- Chairman of the Board, Istari Oncology, Inc.
Other Current Public Company Directorships
- Taysha Gene Therapies, Inc., Chairman of the Board (NASDAQ: TSHA) (since 2020)
